ATC
UTHR icon

Argent Trust Co’s United Therapeutics UTHR Stock Holding History

Argent Trust Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,006
Closed -$225K – 682
2023
Q1 		$225K Sell
1,006
-269
-21% -$66.3K 0.01% 488
2022
Q4 		$355K Buy
1,275
+242
+23% +$61.1K 0.02% 396
2022
Q3 		$217K Buy
1,033
+74
+8% +$16.5K 0.02% 475
2022
Q2 		$226K Buy
+959
New +$195K 0.02% 484
2022
Q1 		– Sell
-1,020
Closed -$221K – 557
2021
Q4 		$221K Buy
+1,020
New +$200K 0.01% 520

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Argent Trust Co's UTHR Position: Q2 2023 in Review

Argent Trust Co sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 1,006 shares — an estimated $225K sold.

Argent Trust Co first reported a position in UTHR in Q4 2021 and held it in 5 quarters. The position peaked at $355K in Q4 2022. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

  • Argent Trust Co reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Argent Trust Co sold 1,006 United Therapeutics shares in Q2 2023, an estimated $225K.
  • Argent Trust Co first reported a position in United Therapeutics in Q4 2021 and held it in 5 quarters.
  • Argent Trust Co's United Therapeutics position peaked at $355K in Q4 2022.
  • 473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Argent Trust Co's 13F filing for Q2 2023, filed 11 Aug 2023.